[Regional transarterial infusion of autologous lymphokine-activated killer (LAK) cells for advanced renal cell carcinoma and its preliminary clinical result]

Nihon Hinyokika Gakkai Zasshi. 1989 Jan;80(1):28-34. doi: 10.5980/jpnjurol1989.80.28.
[Article in Japanese]

Abstract

We herein report the preliminary but appreciable results of regional transarterial infusion of 2 gravity subtypes of autologous lymphokine-activated killer (LAK) cells into the metastatic sites in combination with systemic recombinant interleukin-2 (rIL-2) administration in 3 patients with advanced renal cell carcinoma. Leukapheresis was performed once a week and peripheral blood lymphocytes were separated into 2 different subtypes by Percoll gradient centrifugation. These lymphocytes were incubated with rIL-2 for a few days to induce LAK cells. LAK cells were transferred to the metastatic lesions through cannula twice a week. A large iliac bone metastasis disappeared 3 months after the initial LAK cell therapy via a superior gluteal artery. A case of complete disappearance of psoas muscle and para-aortic lymphnode metastasis as well as partial regression of a lumbar bone metastasis was seen after lumbar arterial infusion treatment. Another case with brain metastasis showed a rapid exacerbation of brain edema after one week's LAK therapy. Our treatment modality seems to be worthwhile and promising for treatment of the advanced renal cell carcinoma.

Publication types

  • English Abstract

MeSH terms

  • Adult
  • Bone Neoplasms / secondary
  • Bone Neoplasms / therapy
  • Brain Neoplasms / secondary
  • Brain Neoplasms / therapy
  • Carcinoma, Renal Cell / secondary
  • Carcinoma, Renal Cell / therapy*
  • Evaluation Studies as Topic
  • Female
  • Humans
  • Immunization, Passive* / methods
  • Infusions, Intra-Arterial
  • Interleukin-2 / pharmacology
  • Interleukin-2 / therapeutic use
  • Kidney Neoplasms / pathology
  • Kidney Neoplasms / therapy*
  • Killer Cells, Natural / transplantation*
  • Lymphocyte Activation
  • Male
  • Middle Aged
  • Recombinant Proteins / pharmacology
  • Recombinant Proteins / therapeutic use
  • Transplantation, Autologous

Substances

  • Interleukin-2
  • Recombinant Proteins